$6.75
+0.20 (+3.05%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PGEN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Squarepoint Ops LLC, +5 more) · FINRA short interest 11.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Zopa Retreatment and Vector Shedding in Adults With RRPNCT06538480Cohort 1 Vector sheddingNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Zopapogene imadenovec (Zopa) | Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae | 30 | 2027-12-02 | in 470 d | 2025-12-15 |
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerNCT06157151Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.Open-label · Treatment | Phase 2 | Recruiting | Biological: PRGN-2009 plus Pembrolizumab | Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | 24 | 2026-11-11 | in 84 d | 2026-04-23 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT03907527Incidence of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: PRGN-3005 UltraCAR-T cells, PRGN-3005 UltraCAR-T cells | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8 | 71 | 2024-12-15 | — | 2024-11-08 |
| PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSNCT03927261Number of Participants who Experience Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: PRGN-3006 T Cells | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 88 | 2024-08-01actual | — | 2024-11-08 |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory PapillomatosisNCT04724980Determine the percentage of subjects with a complete response following treatment with PRGN-2012Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2, PRGN-2012 - Phase II; Dose Level 2 | Recurrent Respiratory Papillomatosis, Papillomavirus Infections, Papillomaviridae | 38 | 2024-06-05actual | — | 2025-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19